Pre-conference AI in pharmacometrics workshop and four scientific poster presentations highlight PumasAI’s presence at the American Conference on Pharmacometrics
NATIONAL HARBOR, Md. and DOVER, Del.— PumasAI,an AI-powered clinical pharmacology and pharmacometrics company transforminghow pharmaceutical teams work, today announced its scientific program for theAmerican Conference on Pharmacometrics (ACoP 2026), taking placeOctober 11-14, 2026, at the Gaylord National Resort & Convention Center inMaryland.
PumasAI will bring a full-day pre-conference workshopon the future of AI in pharmacometrics, four scientific poster presentations,and a team of experts at Booth #5. On October 11 from 9 a.m. to 5 p.m. EST, Dr.Niklas Korsbo will lead AI in Pharmacometrics: A Strategic Vision forthe Next Five Years.
Designed for pharmacometrics leaders, R&D decisionmakers, and quantitative scientists, the workshop will explore the strategicand technical foundations of machine learning in pharmacometrics. The sessionwill focus on how AI and machine learning can support pharmacometric thinking,decision making, and future modeling strategies.
“ACoP brings together many of the people defining whatcomes next for pharmacometrics and model-informed drug development,” said Dr.Vijay Ivaturi, Co-Founder and CEO of PumasAI. “This year, we are especiallyexcited to contribute to the conversation around how AI and Scientific MachineLearning can help scientists move from increasingly sophisticated models tobetter and faster drug development decisions.”
Four PumasAI PosterPresentations at ACoP 2026
PumasAI scientists will also present research spanningpopulation pharmacokinetics, exposure-response analysis, and AI-enabledmodeling:
● Population Pharmacokinetic Analysisof Taletrectinib in Healthy Subjects and Patients with ROS1-Positive (ROS1+) Non-SmallCell Lung Cancer (NSCLC)
● DeepNLME Autonomously RivalsExpert-Specified Pharmacokinetic Functions for Mosunetuzumab
● Population PharmacokineticAnalysis of An Oral Meloxicam Formulation (MR-107A-02) in Healthy Volunteersand Surgical Patients
● Meloxicam (MR-107A-02)Exposure-Response of Pain Relief in Post-Surgery Patients
“The research we are bringing to ACoP spans the workpharmacometricians are doing today and emerging approaches that could changehow that work is done tomorrow,” added Dr. Ivaturi. “That is an exciting placefor PumasAI to be.”
Attendees can visit Booth #5 throughout ACoP 2026 todiscuss pharmacometrics, MIDD, AI, and Scientific Machine Learning. Learn moreabout PumasAI at ACoP 2026 and register for the pre-conference workshop at https://pumas.ai/events/acop-2026-from-models-to-medicines-faster.
About PumasAI
PumasAI is an award-winning global healthcare intelligence companywith a vision to accelerate precision healthcare to patients. Proprietarysoftware and AI tools developed by the company includes the Pumas suite ofproducts, an integrated modeling and simulation platform designed to multiplyproductivity across the drug development lifecycle. Scientists at PumasAIprovide consulting with leading pharmaceutical innovators in clinicalpharmacology, model-informed drug development (MIDD), pharmacometrics,front-end applications, and more.
For additional information, visit www.pumas.ai
Media Contact
Don F. McLean, McLean Media
+1-734-716-4182